title: Symetis ACURATE TA valve.
abstract: The transcatheter aortic valve prosthesis ACURATE TA (Symetis SA, Ecublens, Switzerland) has been specifically designed for transapical access with a future transfemoral version under development. The concept relies on a self-expandable nitinol stent housing a regular porcine bioprosthesis. A unique two-step implantation technique facilitates intuitive positioning. Two pre-approval multicentre trials have demonstrated promising results especially as regards a low rate of paravalvular leaks. The device obtained CE mark at the end of 2011 and is currently commercially available in Europe. This manuscript focuses on the technical details of this new transapical TAVI device and its specific implantation technique.
authors.affiliation: Department of Cardiac Surgery, Kerckhoff Clinic Bad Nauheim, Bad Nauheim, Germany.
authors.forename: Jörg
authors.initials: J
authors.lastname: Kempfert
authors.forename: Helge
authors.initials: H
authors.lastname: Möllmann
authors.forename: Thomas
authors.initials: T
authors.lastname: Walther
mesh_terms: D001022:Aortic Valve Insufficiency / Q000209:etiology / Q000517:prevention & control; D001024:Aortic Valve Stenosis / Q000503:physiopathology / Q000628:therapy*; D001705:Bioprosthesis; D006328:Cardiac Catheterization / Q000009:adverse effects / Q000295:instrumentation*; D062906:Cardiac Catheters; D019317:Evidence-Based Medicine; D006350:Heart Valve Prosthesis; D019918:Heart Valve Prosthesis Implantation / Q000009:adverse effects / Q000295:instrumentation* / Q000379:methods; D006439:Hemodynamics; D006801:Humans; D018579:Patient Selection; D011474:Prosthesis Design; D018570:Risk Assessment; D012307:Risk Factors; D016896:Treatment Outcome